A census of pathway maps in cancer systems biology

Abstract

A key goal of cancer systems biology is to use big data to elucidate the molecular networks by which cancer develops. However, to date there has been no systematic evaluation of how far these efforts have progressed. In this Analysis, we survey six major systems biology approaches for mapping and modelling cancer pathways with attention to how well their resulting network maps cover and enhance current knowledge. Our sample of 2,070 systems biology maps captures all literature-curated cancer pathways with significant enrichment, although the strong tendency is for these maps to recover isolated mechanisms rather than entire integrated processes. Systems biology maps also identify previously underappreciated functions, such as a potential role for human papillomavirus-induced chromosomal alterations in ovarian tumorigenesis, and they add new genes to known cancer pathways, such as those related to metabolism, Hippo signalling and immunity. Notably, we find that many cancer networks have been provided only in journal figures and not for programmatic access, underscoring the need to deposit network maps in community databases to ensure they can be readily accessed. Finally, few of these findings have yet been clinically translated, leaving ample opportunity for future translational studies. Periodic surveys of

A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction

“…However, it is unconvincing to use a single lncRNA as a target due to the significant heterogeneity of GBM (26). More recently, the molecular research and gene exploration of the tumor, especially the statistical analysis research based on big data, has made rapid progress (27,28). Polygenic research has become the focus of this field.…”

Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells

“…Moreover, since we currently do not understand the clinical implications of the majority of cancer mutations, there is little consensus on what genes should be included in these pan-cancer mutation panels (Nguyen and Gocke, 2017) or on how physicians should act on the results. An increase in the number of clinically meaningful cancer mutations, facilitated by interpretable machine learning models such as DrugCell, could further motivate the case for complete genomic sequencing of cancer patients (Katsanis and Katsanis, 2013;Kuenzi and Ideker, 2020).…”

A Roadmap to Immunotherapy: Lesson from the Hallmarks and Signaling Pathways of Cancer

“…During the last decade, the exponential development of high-throughput technologies (such as microarray and next-generation sequencing (NGS)) has produced new gene expression profiling strategies [211]. More recently, the single-cell analysis allowed discovering new dimensions that will possibly monitor the trajectories of distant cell lineage in tumor progression.…”